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Introduction
High blood pressure (BP) is associated with adverse cardiovascular
outcomes.1 A number of highly effective pharmacological therapies
are available to treat hypertension but a substantial proportion of
affected subjects remain inadequately controlled world-wide.2 There
are many reasons for this situation, such as lack of access to treat-
ments, physician inertia, inadequate dosing or combinations of treat-
ments, suboptimal patient adherence to treatment, the use of
interfering drugs or substance of abuse, the presence of undiagnosed
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secondary hypertension or of treatment-resistant hypertension.
A large number of patients with hypertension are reluctant to take or
adhere to pharmacotherapeutic regimens, because of interference
with their daily lives, fear/experience of side effects, preferences for
alternative medications, or other reasons.3 Treatment-resistant
hypertension is commonly defined as BP level above target [office
systolic BP (SBP) >_140 mmHg or diastolic BP >_90 mmHg] despite
treatment with at least 3 antihypertensive medications in adequate
doses, one of which should be a diuretic.4
The difficulty of treating hypertension, its high prevalence and
severe consequences, and the absence of novel antihypertensive
drugs on the horizon and the limitations of purely pharmacologic
approaches have prompted the development of interventional
approaches to provide complementary treatments. Several device-
based approaches have been invented and subsequently tested; one
which has received much positive as well as skeptical attention is
catheter-based renal denervation (RDN).5,6 The method uses radio-
frequency energy, alternatively ultrasound or chemical ablation, to
disrupt renal nerves within the renal artery wall, thereby reducing
sympathetic efferent and sensory afferent signalling to and from the
kidneys.7 Historical observations showed that surgical sympathec-
tomy can reduce BP as well as morbidity and mortality in patients
with uncontrolled hypertension.8 Even though based on strong
pathophysiological rationale,8 catheter-based RDN has not conclu-
sively demonstrated its value for the treatment of resistant hyperten-
sion and its place in the therapeutic armamentarium remains
uncertain.9–12 Other device-based approaches under investigation
include the creation of a central iliac arteriovenous (AV)–anastomo-
sis with a coupler, the stimulation of the carotid sinus, the ablation of
the carotid body, and stent-based expansion of the carotid bulb.13,14
The multidisciplinary European Expert Group has previously pub-
lished proceedings from their 2014 clinical consensus conference aim-
ing at exploring the gaps in our knowledge about RDN and making
recommendations of future randomized controlled trial design.6 A
follow-up conference was convened in October 2016 to evaluate the
position of device therapies for hypertension in the light of the latest
clinical developments. This article presents the main conclusions from
this event. We first present a survey of the changing clinical environ-
ment surrounding hypertension and its implications for clinical trials in
the field. This is followed by an update on currently on-going clinical
trials of device-based hypertension therapy and design considerations
for further trials. Finally, needs and recommendations on the standar-
dised assessment of emerging device therapies are discussed.
What is the impact of recent
hypertension trials on the design of
device-based hypertension studies?
Since the last consensus conference in 2014, several clinical trials
have been published, which may influence how device-based thera-
pies are viewed and investigated. The results raise questions around
treatment regimens, BP targets, and the most appropriate way to
measure BP.
Spironolactone and PATHWAY-2
In patients with resistant hypertension, the option of adding a fourth
antihypertensive drug has been investigated. The crossover trial
PATHWAY-2 recently showed spironolactone to be superior to pla-
cebo as an add-on in patients with resistant hypertension who had
been identified by renin profiling as potential responders to the ther-
apy.15 Despite the positive results from PATHWAY-2, the Expert
Group has discussed whether these results should prompt adding
spironolactone as a fourth line treatment in the management of
resistant hypertension to define a trial population for device-based
proof of concept studies. In the PATHWAY-2 trial, patients were on
a low-dose of bendroflumethiazide, a drug less effective than chlor-
thalidone or indapamide, which may have favoured the BP response
to spironolactone; BP response was not analysed per aldosterone
levels, body mass index or BP at baseline; the short time (6 weeks) of
exposure to the maximum dose of spironolactone (50 mg/d) was
insufficient for an accurate assessment of the long-term tolerability of
this drug; and there are no data on efficacy and safety in patients with
eGFR <45 mL/min/1.73 m2 since they were excluded from the trial.
Moreover, in clinical practise spironolactone has a challenging toler-
ability profile with higher rates of intolerance than in PATHWAY-2,
including gynecomastia and erectile dysfunction, which may cause
treatment interruption or termination at the request of the health-
care provider or patient.16 Indeed, an unexpectedly low rate of side
effects occurred in the PATHWAY-2 study, possibly because of the
relatively short treatment duration.
Based on these reservations, the European Expert
Group felt that there is no need to mandate failure
to control BP on spironolactone as an inclusion crite-
ria for resistant hypertension patients in a proof-of-
concept trial of device-based hypertension therapies.
Blood pressure targets
The results from Systolic Blood Pressure Intervention Trial (SPRINT)
have generated a vivid discussion around treatment targets and the
most appropriate way to measure office BP. SPRINT reported a sig-
nificantly lower risk for cardiovascular disease outcomes and all-
cause mortality by targeting SBP <120 mmHg compared with
<140 mmHg in a population of hypertensive persons with >_1 addi-
tional cardiovascular risk factor.17 The SPRINT results have been
interpreted as supporting a lower recommended target SBP than the
currently widely accepted 140 mmHg. An expedited review of the
SPRINT study was undertaken by the Canadian Hypertension
Education Programme, which led to the recommendation that in
selected high-risk patients, intensive BP reduction to target SBP
<_120 mmHg should be considered to lower the risk of cardiovascu-
lar events.18 From a safety standpoint, it is generally accepted that
there is very low risk for harm from further SBP reductions below
140 mmHg.19,20 However, several design idiosyncrasies in the
SPRINT study are relevant to the discussion on the most appropriate
method to measure BP in clinical trials. SPRINT is the only outcomes
trial to date to have used automated, unattended BP measurements
with a dedicated device. This was done to reduce the influence of the
presence of physicians or other healthcare professionals, or ‘white
coat hypertension’. Though two other major blood pressure trials,
Secondary Prevention of Small Subcortical Strokes (SPS3)21 and
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes
Mellitus (ACCORD),22 also used automated BP devices but with less
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standardized unattended BP measurement than in SPRINT. It has
been noted that unobserved measures of SBP may be 5–15 mmHg
lower than BP measured manually, or when patients are being
observed.23 Previous studies in treated hypertensive subjects have
shown that automatic unattended office BP measurements may be
even lower than daytime ambulatory SBP, and up to 20 mmHg lower
than conventional attended auscultatory office SBP.24 Finally, a recent
meta-analysis of intervention trials on the effects of more or less
intense BP lowering on outcome, which included SPRINT data, has
provided evidence that a significant reduction in the absolute risk of
events occurred whenever systolic BP was reduced below 150, 140,
or even 130 mmHg, although the absolute reduction in risk of events
was smaller when aiming at a systolic BP reduction <130 mmHg.25 In
parallel, however, another recent meta-analysis of intervention trials
by the same group has clearly shown that the lower the systolic BP
achieved by treatment, the higher the number of patients who dis-
continued their drug therapy because of treatment-related side
effects, which indicates a failure in achieving patients’ protection
through pharmacological hypertension management.26
As target BP in a clinical trial of device-based ther-
apy in hypertension, the European Expert Group rec-
ommended an attended target seated office
BP< 140mmHg using the conventional method
and a validated device. Whichever method is used,
it is critical that consistency is maintained in all
centres and at all visits.
The recommended target is closely related to clinical practice, in
line with current guidelines as well as with our previous recommen-
dations. It is also the target used in many currently on-going clinical
trials, although their primary efficacy endpoint is the ambulatory BP
(see below). The European Expert Group further pointed out that
having too ambitious targets may cause trials to count as failed even if
they achieve substantial and significant BP reductions.26 The alterna-
tive of using BP measurements at home was also discussed.
Complementary to ABPM, home BP monitoring may favour BP con-
trol and patient adherence to treatment and is included in the most
recent guidelines from the European Society for Hypertension.27
A number of electronic tools and smartphone apps are emerging to
simplify the procedure for patients and its interpretation by
physicians.28
Considering the less well established standardization
of home compared with ABPM, the European Expert
Group does not recommend using home BP meas-
urement as a primary endpoint in clinical trials,
while there is large agreement that it can be used as
a secondary endpoint. Furthermore, in device trials
home BP monitoring may conceivably influence
adherence if the trial includes hypertensive individu-
als attracted to the therapy as a non-drug solution.
Clinically meaningful blood pressure reduction
A related question to calculating the power and sample size of clinical
trials is what degree of BP reduction associated with a clinically mean-
ingful response. Two recent meta-analyses support a reduction of 8.4
and 10 mmHg in office BP as clinically meaningful, respectively.29,30
These numbers have long been used in the power calculation for clin-
ical studies and is comparable to what can typically be achieved with
one antihypertensive drug. These numbers are intended for power
calculations only. A smaller, but statistically relevant reduction in BP
would still constitute a proof of concept in a controlled study of
device therapies. It is also highly desirable to reduce BP variability
among trial populations.
For the purpose of power calculations in hyperten-
sion device trials the European Expert Group consid-
ered a 10mmHg reduction in office SBP to be a
clinically meaningful outcome. This corresponds to
6-7mmHg in ABP.31 For all BP targets the method
of measurement should be specified. The group
reinforced that ABP should be the primary efficacy
parameter in device trials of hypertension.
Which device-based randomized
controlled trials are ongoing and
currently recruiting patients?
Renal denervation
After the publication of the neutral results with RDN in the sham-
controlled randomized Symplicity-HTN-3 trial in 20149 there was a
transient gap in clinical trials of RDN. Trialists have learned from the
earlier trials (Table 1) and the activity has picked up again in recent
years. Thus, a number of randomized trials are investigating RDN in
patients with resistant hypertension as well as in untreated hyperten-
sive patients (Table 2). Since BP-lowering is a long-accepted surrogate
marker, there is no need for a mortality/morbidity trial with RDN a
priori, as long as the technology is efficient in lowering BP in a
randomized controlled trial with a good safety profile.
• The Symplicity Spyral multi-electrode RDN system is studied in
patients with uncontrolled hypertension in the absence (SPYRAL
HTN OFF-MED; NCT02439749) and presence (SPYRAL HTN
ON-MED; NCT02439775) of antihypertensive medications
(Table 2).32 These trials have a primary efficacy endpoint of change
in 24-h SBP from baseline to 3-month post-procedure. The con-
trol groups receive sham treatment with renal angiography.
• RADIANCE-HTN (NCT02649426) compares the ReCor Medical
Paradise ultrasound system to a sham procedure with the primary
endpoint change in average daytime ambulatory SBP from baseline
to 2 months post-procedure in two separate on- (TRIO) and
off-medication (SOLO) cohorts of patients with uncontrolled
hypertension. In the TRIO cohort, participants with resistant
hypertension will discontinue their current antihypertensive drugs
and switch to standardised single-pill triple therapy. REQUIRE
(NCT02918305, n = 140) is designed to evaluate resistant hyper-
tension patients on standard of care medication in Japan, and
South Korea.
• REDUCE HTN: REINFORCE (NCT02392351) studies the per-
formance of the balloon-based bipolar Vessix system over a 2-
month period comparing the effects with those from a sham pro-
cedure of percutaneous renal angiography on mean reduction in
daytime ambulatory SBP.
• The design of the EnligHTNed IDE Trial in resistant hypertensive
patients is being finalized in discussion with the US Food and Drug
Administration. The trial is randomized, double-blinded and with
3274 F. Mahfoud et al.
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.sham control. Participants will discontinue their current antihyper-
tensive drugs and switch to standardized single-pill triple therapy
to be maintained at least 12 months after randomization. The pri-
mary efficacy endpoint is reduction in 24-h SBP at 6 months com-
pared with baseline.
• WAVE-IV (NCT02029885) was a sham controlled, double blind
study with the non-invasive ultra-sound based Kona Medical
Surround Sound System for bilateral RDN. This trial used change
in office SBP from screening to 6 months post-randomization as
the primary efficacy end point. The trial was stopped for futility on
19 July 2016 as it had by this time point not demonstrated any dif-
ferences between the groups in either office BP or 24-h ABP.
There had been no safety concerns.
Arteriovenous–anastomosis creation with a coupler
• The ROX II pivotal study will be performed in the USA with the
aim of enrolling 500 patients who will be randomized to coupler
implantation (with a shunt volume of approximately 800 mL/min)
or sham treatment (NCT NCT02895386). Patients should be sta-
ble on three antihypertensive drugs. The primary endpoint is
change from baseline in 24 h systolic ABP at 6 months. The study
will be conducted using a Bayesian approach with the first safety
analysis at 100 and first efficacy look at 250 randomized patients.
Carotid bulb expansion, carotid body ablation, and
baroreflex stimulation
• Carotid bulb expansion (using a dedicated carotid stent,
NCT02804087) and carotid body ablation (using a transvenous
catheter, NCT02099851) are two different approaches, that are
currently being investigated in first-in-man studies. Pending positive
results, randomized-controlled trials will be conducted. In the
Rheos Pivotal Trial, baroreflex stimulation failed to meet its early
safety endpoint. Open label, non-randomized follow-up of the
whole cohort reported that office systolic BP reduction
of > 30 mmHg was sustained up to 53 months with no important
safety concerns.33,34 The Barostim NeoTM system has CE Mark
approval for the treatment of RHTN and for heart failure. The
Economic Evaluation of Baroreceptor STIMulation for the
Treatment of Resistant HyperTensioN (ESTIM-rHTN) trial, funded
by the French Ministry of Health, is ongoing and aims to study bar-
oreceptor activation in patients with resistant hypertension and
eGFR 30 mL/min per 1.73 m2 or higher (NCT02364310).35
What factors should be
considered in future clinical
studies for emerging device
therapies in hypertension?
(1) A sham control group is a prerequisite for a successful proof-of-
concept trial of device-based therapies in hypertension. The major-
ity of the trials listed above include a sham treatment. There was an
initial controversy around the need for a sham group in trials investi-
gating the BP lowering efficacy of device-based treatments for
hypertension, but at present, this requirement met near-unanimous
support. However, the use of a sham procedure is associated with
certain degree of complexity, including the ethics of performing a
procedure conferring an immediate risk of adverse event in those
trials recruiting especially untreated patients with Grade I to II
hypertension who are at low immediate cardiovascular and cere-
brovascular risk. A blinding index should be used to assess the effi-
cacy of blinding in clinical device trials.36 The index can be used for
any blinded group, not only study subjects and researchers. An
....................................................................................................................................................................................................................
Table 2 Differences between a first generation (SYMPLICITY HTN-3) and latest generation clinical trial (SPYRAL
HTN)
First generation RCT
(SYMPLICITY HTN-3)
Latest generation RCT (SPYRAL HTN Global
Clinical Trial Programme)
Technology Single-electrode catheter Multi-electrode catheter
Ablation pattern Main vessels Main, accessory, and branch vessels
Proceduralist’s experience Varied level of experience Experienced proceduralists, including many sites with sig-
nificant familiarity with the procedure
Regimen Range of medication regimens allowed for
enrolment
Medication regimen required for enrolment is standardized
Absence of medications Data only obtained for patients taking anti-hyperten-
sive medications
Data also obtained for patients not taking antihypertensive
medications
Maximum dose Patients required to be on maximum tolerated dose,
with an average of >5 anti-hypertensive
medications
Patients not required to be on maximum tolerated dose
Adherence No medication adherence protocol Witnessed intake (on medication arm) and medication
adherence analysis (both arms)
Disease severity Patients with severe hypertension with an average of
>10 years of treatment without control
Patients with severe to moderate hypertension due to
lower OSBP entry criteria and no maximum tolerated
drug requirement
BP measurement Office blood pressure at 6 months as primary end-
point; may have included white coat population
ABPM at 3 months as primary measure
Geography US patients only Global study
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.assessment of appropriate blinding is particularly important in
randomized controlled device trials where proper blinding can be
highly challenging.
(2) A run-in phase with repeated BP assessments (office and ABP meas-
urements) should be mandatory in clinical device trials in hyper-
tension to reduce bias introduced by regression to the mean.37
For trials of treatment resistant populations, therapeutic regimens
should be consistent between the groups. The need for consistency
of pharmacotherapeutic regimens was emphasized in the earlier
consensus document.6 For trials in drug-treated populations, a
standardized, stepped titration scheme used in trials with antihy-
pertensive drugs, e.g. The LIFE study38 or the DENER-HTN
trial10 is a highly desirable design component to reduce heteroge-
neity and ensure that all patients receive appropriate cardiovascu-
lar protection. No established and validated tool exists to adjust
BP changes after an intervention, if dose or drug regimen has
been changed.
(3) Several trials currently investigate patients with Stage 1 or 2 hyperten-
sion but not treated with pharmacotherapy. This may be a more suitable
population than treated resistant patients to demonstrate proof of
concept for new technologies. It would also show whether device-
based interventions can reduce or eliminate the need for antihyper-
tensive drugs in achieving BP control and whether it may affect the
efficacy of drugs. However, these trials may face potential ethical
objections, as the patients would forgo treatment with long-
established pharmacotherapies and treatment regiments would not
be in accordance with the recommendations of international
Guidelines. The European Expert group acknowledged this objection
in the earlier consensus publication.6 However, studies in untreated
hypertensive patients can be adapted to meet ethical considerations.
A follow-up period of 3months would reduce the risk to patients from
uncontrolled hypertension and may be sufficient to demonstrate effi-
cacy in a proof of concept trial. If the results are positive, further stud-
ies will be performed in settings applicable to clinical practice to
investigate the persistence of the effects. An appealing study design is
to follow patients until the primary efficacy endpoint is reached and
then to introduce a stepped antihypertensive drug regimen in both
groups (Take home figure). Such a design would provide the best
possible therapy to all patients as well as provide data on whether the
intervention affects the response to pharmacotherapy.
(4) By considering patients’ preference in the study design, it may be
possible preferentially to enrol patients who are actively demanding
a non-pill based therapy. In the experience of the group members, a
number of hypertensive individuals, particularly those of younger
age, are reluctant to start on a potentially lifelong pharmacotherapy
regimen. In such situations, ethical concerns would be less of an
impediment to enrolment as long as patients provide informed con-
sent to randomization, including the possibility of undergoing a
sham procedure.
(5) It has to be considered that device-based therapies may lower BP
more effectively in the presence of antihypertensive drugs in
patients with resistant hypertension, which implies the need for clin-
ical studies with standardized concomitant drug treatment.
(6) It would be desirable to maximize adherence to oral antihyperten-
sive treatment and lifestyle modification measures as much as possi-
ble. Modern technologies such as mass spectrometry have made it
easier to measure drug adherence in simple urinanalyses39 and the
methods have been used to assess adherence as a factor in resistant
hypertension before and after RDN.40,41 The method would
deserve to be explored for use in trials as an alternative to elec-
tronic monitoring of pill packages. However, adherence should not
be the main focus of a trial of device therapies as the topic itself
needs more research. Nevertheless, the European Expert Group
considered that urinalysis/toxicological testing is desirable and should,
therefore, be encouraged in all trials of device therapies for hyperten-
sion. Alternative methods include directly observed medication
intake and simultaneous ABP recording.
(7) The European Expert Group further emphasized that the large
number of on-going studies in the field provides a unique opportu-
nity to perform prospectively designed meta-analyses, and economic
evaluations, not only on the therapies but also on the effects of
sham procedures. Since current trials have similar inclusion and
exclusion criteria, a patient based meta-analysis increases the power
to precisely assess, which patient group benefits most from RDN.
The group strongly recommends the establishment of an independ-
ent research collaboration which should be granted access to all data
Take home ﬁgure Suggested flow chart for trial of renal denervation in hypertensive patients initially off drugs.
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from all sponsors to conduct a meta-analysis based on individual
data. Country-specific economic evaluations, using fully pooled data
on the use of healthcare resources and country-specific values for
unit costs should be encouraged to inform policy makers.
Whenever possible, the results should be analysed according to
adherence to therapy.
What information will the ongoing
studies provide and what are potential
outcome scenarios?
Why are the trials recruiting slowly and
how to improve recruitment rates?
The problems with slow recruitment and difficulties finding appropri-
ate patients need to be overcome to run sufficiently large trials
within a reasonable time frame. Most trials of device therapies in
hypertension are bedevilled by slow recruitment. In one by no
means unique example, the DENERHTN trial screened 1416
patients over a 17-month period to identify 106 patients who were
enrolled in the trial.10 For trials in treatment resistant patients, the
need to show insufficient response to a large number of medica-
tions before qualifying complicates patient selection. Patients are
often reluctant to be potentially assigned to a sham arm, which may
be particularly relevant in those patients who are not on pharmaco-
therapy. To increase the attractiveness of clinical trials it would be
necessary to counter the prevailing negative image of sham treat-
ment. Sham is known to reduce BP, as seen in all device trials. A
meta-analysis found average SBP reductions of around 9 mmHg in
the placebo/sham arms in trials of resistant hypertension.42 In the
experiences of the members of the European Expert Group, there
is no placebo effect from everyday renal angiography in hyperten-
sive patients, but the same procedure reduces BP when used as
sham in a clinical trial.
To increase recruitment patients should be informed
about the nature and the rationale of the sham pro-
cedure. In addition, all patients should be offered
the active treatment if the trial eventually shows to
be positive.
A pro-active information strategy should be implemented
with respect to referrals, communications and screening. A
more patient-centric approach should be considered, taking
advantage of electronic media and information technology
when possible. Recruitment campaigns and newsletters need to
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......................................................................................................
On
medication
Off
medication
Comments
Positive Positive The concept works. The devices defi-
nitely reduce BP.
• RDN should be investigated in the
whole spectrum of confirmed
hypertension regardless of the
antihypertensive pharmacological
treatment.
New trials are needed to explore:
(1) The clinical phenotypes of
patients that had the best BP
response to RDN and further
study RDN in these settings.
(2) Investigate different procedural
aspects including catheter
design, modality, and ablation
strategy.
(3) Assess the effect of RDN on
long-term cardiovascular and
renal risk in hypertension,
chronic kidney and heart failure
patients.
(4) Potential new indications for
RDN such as heart failure,
chronic kidney disease,
arrhythmias.
Negative Negative The concept does not work in hyperten-
sion with the current technology
• New trials may be considered to test:
(1) Alternative methods of radio-
frequency RDN like chemical
and/or ultrasound ablation.
(2) Evaluate if there are subgroups
(i.e. younger age, higher base-
line BP, obese) with favourable
effects on BP in patients with or
without antihypertensive drug
therapy and further study RDN
in these patients.
Positive Negative The concept partially works. RDN
reduces BP in specific settings.
New trials may be considered to:
Continued
......................................................................................................
Continued
On
medication
Off
medication
Comments
(1) Select the appropriate clinical
hypertension phenotype (later
stages, resistant hypertension,
higher baseline BP, synergistic
effect with specific drugs).
(2) Determine long-term efficacy.
Negative Positive The concept partially works. RDN
reduces BP in specific settings.
New trials may be considered to:
(1) Select the appropriate clinical
hypertension phenotype (early
stages, young, intolerance to
drugs, attenuated effects by
concomitant drug treatment).
(2) Determine long-term efficacy.
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target patients in addition to the current focus on investigators.
Today’s patients are highly connected and informed, and should
be approached as partners, or e-patients (Table 3) in an effort to
bring the trial to the patient. Young, hypertensive but otherwise
healthy people are mainly treated by general practitioners, not
cardiologists or hypertension specialists. To identify, contact
and recruit these individuals, innovative approaches may be nec-
essary. On the side of the investigators, less complex trials with
fewer recorded variables, limited number of focused end points
and simplified case report forms would reduce the workload
and may increase the willingness to take part in the trial.
The help of patient’s organisations should be
actively solicited. As has been seen in e.g. cancer or
HIV, if a study is attractive patients actively seek
opportunities for participation. The appropriate posi-
tioning of device studies is necessary to achieve simi-
lar effects.
What are unmet needs in the assessment
of device therapies for hypertension?
(1) There is an urgent need to develop simple and reproducible intra-
procedural technologies to evaluate the extent of nerve ablation.
Promising markers have been suggested, such as the periprocedural
veno-arterial noradrenaline gradient (the veno-arterial difference).
Greater periprocedural renal veno-arterial noradrenaline gradient
reduction during RDN was associated with greater BP responses at
3 and 6 months post-procedure.43 Another suggested predictor of
response are BP changes induced by renal nerve stimulation before
vs. after the procedure, which correlate with changes in 24-h ABPM
3–6 months post-procedure.44 Whether any of these methods can
be adapted for routine clinical use is unclear, however. Imaging tech-
niques such as transluminal imaging of renal nerves using optical
coherence tomography have been suggested as a potential tool to
assess the geometry and state of the renal artery and optimise the
denervation procedure.45 All of these tools have yet to be investi-
gated in controlled trials. If they can be successfully validated, tools
for procedural guidance should be consistently integrated into future
study protocols. At present the European Expert Group considers
that no tool for intraprocedural assessment has demonstrated sufficient
usefulness to warrant a recommendation for generalized use.
(2) The first systems for RDN employed radiofrequency energy in a
manner analogous to ablation for cardiac conditions such as atrial
fibrillation. This approach is still widely employed, but a number of
alternative technologies are being developed, for instance based on
alcohol injection, high-frequency ultrasound or low-intensity
focused ultrasound.14 Even within the same approach, electrode
designs vary, with spiral, basket or helical radiofrequency multi-
electrodes and other designs for non-radiofrequency technologies.
Since the space is crowded, it is critical to uphold consistent criteria
for the evaluation of emerging technologies. Too little is known
about the clinical effects of the different devices. A class effect from
RDN remains to be demonstrated. It is unlikely that all devices in
development will be equally effective, let alone successful. Based on
these considerations, the European Expert group strongly recom-
mend that all devices be tested preclinically, more appropriately in
hypertensive animal models (obese dog or swine), as a prerequisite
for first-in-man evaluation and market approval.
(3) Most preclinical studies have been performed in healthy, normoten-
sive porcine models and there remains a need for a model that is
more closely related to human hypertension. One interesting
model of modern human hypertension may be the Ossabaw breed,
which appears to represent a translationally relevant model of
hypertension with its associated comorbidities. RDN reduces diet-
induced hypertension in this model.46 A suitable, hypertensive ani-
mal model with long-term follow-up would greatly help to further
assess the BP effects and other surrogate markers of efficacy, e.g.,
histological denervation and renal noradrenaline content. However,
the peri-arterial renal nerve anatomy in preclinical models differs
from that in humans and it is unclear how applicable these results
are to diseased vessels of patients with hypertension and
atherosclerosis.
(4) It has been shown that arterial microanatomy determines the suc-
cess of energy-based RDN.47 In the future, assessment of the mor-
phology of the arterial wall and the adventitia may be required
before deciding on the most suitable device for each patient. The
optimal degree of contact against the renal artery wall and the
depth, duration and intensity of energy delivery to provide the best
procedural results will need to be investigated and optimized for
each specific renal-denervation technology. As proper dose-response
studies are lacking, there is no reliable information available to guide
these efforts and there is no simple way to assess dose-response in
human subjects currently.
(5) A consistent and appropriate follow-up period between the procedure
and histological examination is critical for the correct assessment of
nerve injury. The correlation between the duration of follow-up on
nerve injury and arterial wall injury is unknown. A related question
is that of nerve regeneration, which has been observed in animal
studies48 but data in humans are very limited. The possibility and
clinical implications of nerve regeneration in humans need to be
clarified with long-term follow-up of patients.
(6) The safety of new devices requires careful monitoring. To enable
accurate comparisons of risk-benefit profiles between different
Table 3 Characterization of e-patients
Equipped Possessing skills to manage their own
condition.
Enabled Make choices about self-care and finding
those choices respected.
Excellent patient-care Promote centre of excellence, centre of
clinical trials, networks.
Engaged Engaged in their own care.
Expert patients Able to improve their self-rated health sta-
tus; cope with generic features of chronic
disease and dependence on hospital care;
able to share their experience and con-
vince other patients.
Evaluating Evaluate not only the information found but
also the source of that information;
establishing trust in sources at an early
stage (website of the trial, information by
and the patient during a trial).
Equal The e-patient expects to be an equal mem-
ber of the team in partnership with pro-
fessionals involved in their care.
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technologies, complications should be documented and evaluated using
consistent terms and methods in all trials with emerging devices. The
European Expert Group considers a 3-6-month follow-up sufficient
to reveal safety signals, as for most other vascular interventions. For
progression of stenosis and long-term vascular safety, longer time
frames need to be considered, which may be different from one
device to another.
(7) Better tools are urgently needed to guide clinical decisions. It is
likely that patient’s characteristics and the underlying patho-
physiology of hypertension contributes to success of the proce-
dure. Patients with isolated systolic hypertension, e.g. show
limited response to RDN therapy,49,50 probably due to
increased aortic stiffness and pressure wave reflection.51
Whether these patients benefit more from other device-
therapies remains to be proven.52
(8) All guidelines and recommendations should be device-specific. The
correlation between morphology and the efficacy of different devi-
ces needs to be systematically assessed before specific recommen-
dations can be issued. The group strongly believes that efficacy and
safety data acquired with a certain device cannot be transferred to
any other device or intervention.
Summary and outlook
The interest in RDN for hypertension has fluctuated recently, with
a flurry of initial enthusiasm followed by sudden loss of interest by
researchers and device manufacturers, with an almost as sudden
resurgence in clinical trials activity and device innovation more
recently. There is widespread consensus that this therapeutic
strategy can be effective, at least for some of the technologies
available. Major uncertainties remain as to the clinical role of RDN,
and whether any of the emerging technologies such as AV–anasto-
mosis formation, carotid body ablation, carotid bulb expansion, or
baroreflex stimulation will have a future as effective treatment
options in patients with hypertension. In our first consensus report
in 2015, the European Expert Group pointed to the major unmet
need of standardization of measurements, trial design and proce-
dural performance.6 With the large number of different technolo-
gies currently in the pipeline, this need has even increased. Only
through high-quality, collaborative research and openness to new
methods for recruitment, patient selection, and assessment of out-
comes will it be possible to establish incontrovertibly whether
device therapies for hypertension are effective and what are pre-
ferred patient populations. Once the proof of concept is estab-
lished, further studies with a design relevant to clinical reality will
be needed to establish the place of new devices in the treatment
armoury. The clinical and research community has a large respon-
sibility to prove or disprove the value of new therapies, in order to
ensure that antihypertensive devices provide future patients with
the greatest benefit and the smallest risk.
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